Latent Mycobacterium tuberculosis Infection.

[1]  E. Bernacki,et al.  T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals. , 2015, American journal of respiratory and critical care medicine.

[2]  R. Chaisson,et al.  Latent Mycobacterium tuberculosis infection. , 2015, The New England journal of medicine.

[3]  W. Lu,et al.  Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. , 2015, The Lancet. Infectious diseases.

[4]  J. Bruun,et al.  HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study , 2014, BMC Infectious Diseases.

[5]  N. Banaei,et al.  False-positive quantiferon results at a large healthcare institution. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  N. Beeching,et al.  Tuberculin Skin Testing and Treatment Modulates Interferon-Gamma Release Assay Results for Latent Tuberculosis in Migrants , 2014, PloS one.

[7]  C. Stein,et al.  Tuberculin Skin Test Reversion following Isoniazid Preventive Therapy Reflects Diversity of Immune Response to Primary Mycobacterium tuberculosis Infection , 2014, PloS one.

[8]  J. Kammerer,et al.  Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. , 2013, American Journal of Epidemiology.

[9]  J. Hackman,et al.  Three months of rifapentine and isoniazid for latent tuberculosis infection. , 2011, The New England journal of medicine.

[10]  Aman Verma,et al.  The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices , 2011, PLoS medicine.

[11]  E. Mylonakis,et al.  4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  F. Cobelens,et al.  LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement , 2009, European Respiratory Journal.

[13]  A. Lalvani,et al.  Screening for tuberculosis infection prior to initiation of anti-TNF therapy , 2008, Autoimmunity reviews.

[14]  D. Menzies.  Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. , 1999, American journal of respiratory and critical care medicine.